Pemafibrate ( DrugBank: Pemafibrate )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
93原発性胆汁性胆管炎2

93. 原発性胆汁性胆管炎


臨床試験数 : 298 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000039350
2020/03/0101/03/2020Clinical benefit of pemafibrate in patients with primary biliary cholangitis (PBC) with dyslipidemiaClinical benefit of pemafibrate in patients with primary biliary cholangitis (PBC) with dyslipidemia - Clinical benefit of pemafibrate in patients with primary biliary cholangitis (PBC) with dyslipidemia primary biliary cholangitispemafibrate for 12 months

bezafibrate for 12 months
Shinshu University Faculty of Medicine, Department of GastroenterologyNULLPending20years-old95years-oldMale and Female60Not selectedJapan
2JPRN-JapicCTI-173728
05/10/201705/10/2017Pharmacokinetic study of K-877 in patients with Primary biliary cholangitisPharmacokinetic study of K-877 in patients with Primary biliary cholangitis Primary biliary cholangitisIntervention name : Pemafibrate
INN of the intervention : Pemafibrate
Dosage And administration of the intervention : Oral dose
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -
Kowa Co., Ltd.NULLcomplete20BOTH8Phase 1Japan